TITLE

Esotropia Induced by a Chemotherapeutic Agent in a Patient with a Brain Tumor

AUTHOR(S)

Bodack, Marie I.

PUB. DATE

December 2014

SOURCE

Optometry & Visual Performance;Dec2014, Vol. 2 Issue 6, p302

SOURCE TYPE

Academic Journal

DOC. TYPE

Case Study

ABSTRACT

Patients who present with a sudden onset esotropia require a complete eye examination with dilation and cycloplegia to differentiate an accommodative from a non-accommodative cause. Non-comitancy, motility dysfunctions, and optic nerve anomalies must be ruled out. Cases of non-accommodative esotropia are often idiopathic but may be associated with neurologic problems. This paper will present a case report of a 6-year-old male who presented with a sudden onset esotropia. He had a prior history of surgical resection of an ependymoma and was currently under treatment with a chemotherapeutic agent. Treatment options for the esotropia are presented.

ACCESSION #

101326787

 

Related Articles

• Vascular normalization: a real benefit? Ribatti, Domenico // Cancer Chemotherapy & Pharmacology;Aug2011, Vol. 68 Issue 2, p275 

  It is well established that antibodies to vascular endothelial growth factor (VEGF) in combination with chemotherapeutic agents produce synergistic cytotoxicity in a range of cancer. In this review article, it has been analyzed whether the so-called vascular normalization of abnormal tumor blood...

• Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging. Jain, Rajan; Narang, Jayant; Sundgren, Pia; Hearshen, David; Saksena, Sona; Rock, Jack; Gutierrez, Jorge; Mikkelsen, Tom // Journal of Neuro-Oncology;Nov2010, Vol. 100 Issue 1, p17 

  Brain tumor patients undergo various combinations therapies, leading to very complex and confusing imaging appearances on follow up MR imaging and hence, differentiating recurrent or progressing tumors from treatment induced necrosis or effects has always been a challenge in neuro-oncologic...

• Acute V Pattern Esotropia Without Abduction Deficit, Secondary to a Posterior Fossa Pilocytic Astrocytoma. Shipman, Tracey L. // Journal of Pediatric Ophthalmology & Strabismus;Jul/Aug2009, Vol. 46 Issue 4, p235 

  A case of acute esotropia with bilateral inferior oblique muscle overaction in a 4-year-old boy with a posterior fossa pilocytic astrocytoma is reported. After tumor excision, the esotropia and oblique dysfunction resolved. Acute esotropia with bilateral inferior oblique muscle overaction...

• Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier. On, Ngoc H.; Miller, Donald W. // Current Pharmaceutical Design;Mar2014, Vol. 20 Issue 10, p1499 

  The delivery of many drugs to the central nervous system (CNS) is limited due to the restrictive nature of the blood-brain barrier (BBB). The reduced paracellular diffusion and the presence of various drug efflux transporters in the brain microvessel endothelial cells forming the BBB make...

• Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Jacus, Megan; Daryani, Vinay; Harstead, K.; Patel, Yogesh; Throm, Stacy; Stewart, Clinton; Jacus, Megan O; Daryani, Vinay M; Harstead, K Elaine; Patel, Yogesh T; Throm, Stacy L; Stewart, Clinton F // Clinical Pharmacokinetics;Mar2016, Vol. 55 Issue 3, p297 

  Despite significant improvement in outcomes for patients with hematologic malignancies and solid tumors over the past 10 years, patients with primary or metastatic brain tumors continue to have a poor prognosis. A primary reason for this is the inability of many chemotherapeutic drugs to...

• Osmotic Blood-Brain Barrier Modification for the Treatment of Malignant Brain Tumors. Haluska, Marianne; Anthony, Margaret L. // Clinical Journal of Oncology Nursing;Jun2004, Vol. 8 Issue 3, p263 

  The blood-brain barrier (BBB) is a physiologic barrier that protects the brain from toxic substances, including most of the chemotherapeutic agents used today. The BBB may be partly responsible for the poor efficacy of chemotherapy for malignant primary or metastatic brain tumors. A technique of...

• Taxane-induced morphea in a patient with CREST syndrome. Bouchard, Susan M.; Mohr, Melinda R.; Pariser, Robert J. // Dermatology Reports;2010, Vol. 2 Issue 3, p23 

  The taxanes, docetaxel and paclitaxel, are microtubule stabilizing chemotherapeutic agents that have demonstrated antineoplastic effects in a variety of solid tumors. They have been linked to the development of localized cutaneous sclerosis in some patients. We present a case of...

• Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model. Jinwei Hu; Xiangpeng Yuan; Ko, MinHee K.; Dali Yin; Sacapano, Manuel R.; Xiao Wang; Konda, Bindu M.; Espinoza, Andres; Prosolovich, Ksenia; Ong, John M.; Irvin, Dwain; Black, Keith L. // Molecular Cancer;2007, Vol. 6, p22 

  Background: The blood-brain tumor barrier (BTB) impedes the delivery of therapeutic agents to brain tumors. While adequate delivery of drugs occurs in systemic tumors, the BTB limits delivery of anti-tumor agents into brain metastases. Results: In this study, we examined the function and...

• Epilepsy in the cancer patient. Kargiotis, Odysseas; Markoula, Sofia; Kyritsis, Athanasios // Cancer Chemotherapy & Pharmacology;Mar2011, Vol. 67 Issue 3, p489 

  Purpose: Epileptic seizures in patients with malignancies usually occur as a consequence of brain metastases from systemic cancer or the presence of a primary brain tumor. Other less-frequent causes include metabolic disorders such as electrolyte abnormalities, hypoglycemia, hypoxia and liver...

Read the Article